KEYCORP TO PRESENT AT THE 2025 RBC CAPITAL MARKETS GLOBAL FINANCIAL INSTITUTIONS CONFERENCE
CLEVELAND, Feb. 25, 2025 /PRNewswire/ — KeyCorp (NYSE: KEY) announced today that Clark Khayat, Chief Financial Officer, will speak at the 2025 RBC Capital Markets Global Financial Institutions Conference on Tuesday, March 4, 2025, at 11:20 a.m. ET in New York City.
KeyCorp plans to review its performance, strategy, and outlook, and the discussion may include forward-looking statements and other material information. The live audio webcast will be available on the day of the conference at www.key.com/ir. If you are unable to join the live webcast, or wish to hear a re-broadcast, access www.key.com/ir and select Events & Presentations.
ABOUT KEYCORP
In 2025, KeyCorp celebrates its bicentennial, marking 200 years of service to clients and communities from Maine to Alaska. To learn more, visit KeyBank Heritage Center. Headquartered in Cleveland, Ohio, Key is one of the nation’s largest bank-based financial services companies, with assets of approximately $187 billion at December 31, 2024.
Key provides deposit, lending, cash management, and investment services to individuals and businesses in 15 states under the name KeyBank National Association through a network of approximately 1,000 branches and approximately 1,200 ATMs. Key also provides a broad range of sophisticated corporate and investment banking products, such as merger and acquisition advice, public and private debt and equity, syndications and derivatives to middle market companies in selected industries throughout the United States under the KeyBanc Capital Markets trade name. For more information, visit https://www.key.com/. KeyBank Member FDIC.
SOURCE KeyCorp
WANT YOUR COMPANY’S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Related news for (KEY)
- Third Coast Bancshares, Inc. and Keystone Bancshares, Inc. Announce Definitive Merger Agreement
- PADCEV™ (enfortumab vedotin-ejfv) Plus KEYTRUDA® (pembrolizumab) sBLA Granted FDA Priority Review for Treatment of Certain Patients with Muscle-Invasive Bladder Cancer
- IO Biotech Presents Phase 3 Results for Cylembio® plus KEYTRUDA® (pembrolizumab) in First-line Advanced Melanoma at ESMO 2025
- PADCEV™ Plus KEYTRUDA™, Given Before and After Surgery, Cuts the Risk of Recurrence, Progression or Death by 60% and the Risk of Death by 50% for Certain Patients with Bladder Cancer
- KEYCORP REPORTS THIRD QUARTER 2025 NET INCOME OF $454 MILLION, OR $.41 PER DILUTED COMMON SHARE
